Johnson & Johnson's Icotrokinra Shows Positive Phase 2 Results for Ulcerative Colitis in NEJM

New data published in the New England Journal of Medicine from Johnson & Johnson's Phase 2 trial of icotrokinra for ulcerative colitis indicates the targeted oral peptide met its primary endpoint of clinical response across all dose groups. This research highlights a new molecular class and a trial design reflecting current FDA evidentiary preferences, potentially influencing future clinical research and treatment strategies for ulcerative colitis.